Ireland
--:--IST
Recruiting Not applicable

Pretreatment With HCQ Before Radiotherapy and Chemotherapy in Advanced NPC Patients

NCT06389201 · tracked via the Priya Life Science China tracker
Phase
Not applicable
Started
2024-08-01
Last updated
2025-02-18

Condition(s) studied

Nasopharyngeal Carcinoma

Investigational drug(s) / intervention(s)

HCQ →Placebo

HCQ: HCQ, 400-600mg, oral tablet, once, one day before chemotherapy and radiotherapy. During therapy, HCQ maintenance dose is 200-400mg daily.

Placebo: Placebo, oral tablet, once, one day before chemotherapy and radiotherapy. During therapy, placebo maintenance oral tablet once daily.

Study summary

Dormant cancer cells that survive anti-cancer therapy can lead to cancer recurrence and disseminated metastases that prove fatal in most cases. Recently, specific dormant polyploid giant cancer cells (PGCC) have drawn the investigators' attention because of their association with the clinical risk of nasopharyngeal carcinoma (NPC) recurrence, as demonstrated by previous clinical data. In study, the investigators report the biological properties of PGCC, and reveal that autophagy is a critical mechanism of PGCC induction. Moreover, pharmacological inhibition of autophagy greatly impaired PGCC formation, significantly suppressing metastasis and improving survival in a mouse model. Mechanistically, chemotherapeutic drugs partly damaged mitochondria, and activated autophagy to promote PGCC formation. High numbers of PGCCs correlated with shorter recurrence time and worse survival outcomes in NPC patients. Collectively, these findings suggest a therapeutic approach of targeting dormant PGCCs in cancer.

Pretreatment with an autophagy inhibitor (HCQ) before chemotherapy and radiotherapy could prevent formation of therapy-induced dormant polyploid giant cancer cells, thereby reducing recurrence and metastasis of nasopharyngeal carcinoma.

Eligibility

Sex
ALL
Min age
20 Years
Max age
70 Years
Healthy volunteers
No
Inclusion Criteria: * Clinical diagnosis of NPC. * Have not received any cancer therapies * Must provide informed consent Exclusion Criteria: * With metastasis before the first treatment.

Primary outcome measure(s)

  • Recurrence and metastasis — Five to Ten years.
    After the patients are diagnosed and treated, CT scans is used semi-annually to determine the progression, recurrence and metastasis of tumor.

Trial sites (1)

FacilityCityRegionStatus
Bo You Nantong Jiangsu Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06389201 on ClinicalTrials.gov ↗ ← All trials in China